Research programme: inflammation therapeutics - Catabasis Pharmaceuticals

Drug Profile

Research programme: inflammation therapeutics - Catabasis Pharmaceuticals

Alternative Names: CAT 1000; CAT 1002; CAT 1040; CAT 1041; CAT 1902; CAT 1904

Latest Information Update: 06 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action NF-kappa B modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy; Inflammation; Inflammatory bowel diseases

Most Recent Events

  • 04 Jan 2017 Preclinical trials in Duchenne muscular dystrophy in USA (PO)
  • 06 May 2013 Preclinical development is ongoing in US
  • 11 Mar 2011 Active development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top